Adverse drug reactions of montelukast in children and adults

Meindina G. Haarman*, Florence van Hunsel, Tjalling W. de Vries

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    44 Citations (Scopus)
    281 Downloads (Pure)

    Abstract

    Montelukast, a selective leukotriene receptor antagonist, is recommended in guidelines for the treatment of asthma in both children and adults. However, its effectiveness is debated, and recent studies have reported several adverse events such as neuropsychiatric disorders and allergic granulomatous angiitis. This study aims to obtain more insight into the safety profile of montelukast and to provide prescribing physicians with an overview of relevant adverse drug reactions in both children and adults. We retrospectively studied all adverse drug reactions on montelukast in children and adults reported to the Netherlands Pharmacovigilance Center Lareb and the WHO Global database, VigiBase((R)) until 2016. Depression was reported most frequently in the whole population to the global database VigiBase((R)) (reporting odds ratio (ROR) 6.93; 95% CI: 6.5-7.4). In the VigiBase((R)), aggression was reported the most in children (ROR, 29.77; 95% CI: 27.5-32.2). Headaches were reported the most frequently to the Dutch database (ROR, 2.26; 95% CI: 1.61-3.19). Furthermore, nightmares are often reported for both children and adults to the Dutch and the global database. Eight patients with allergic granulomatous angiitis were reported to the Dutch database and 563 patients in the VigiBase((R)). These data demonstrate that montelukast is associated with neuropsychiatric adverse drug reactions such as depression and aggression. Especially in children nightmares are reported frequently. Allergic granulomatous angiitis is also reported, a causal relationship has not been established.

    Original languageEnglish
    Article number00341
    Number of pages8
    JournalPharmacology Research & Perspectives
    Volume5
    Issue number5
    DOIs
    Publication statusPublished - Oct-2017

    Keywords

    • Asthma
    • drug safety
    • therapeutic drug monitoring
    • RECEPTOR ANTAGONIST MONTELUKAST
    • ASTHMA
    • NIGHTMARES

    Cite this